Skip to main content
Subarachnoid HemorrhageNutrition and dietSupplementsExercise and fitnessMetabolicDeviceDietary supplement

What this study is

The study purpose is to investigate the hypothesis that in adults with SAH, early neuromuscular electrical stimulation (NMES) and high protein supplementation (HPRO) will improve muscle mass, metabolic and inflammatory biomarker profiles, compared to SAH controls receiving standard of care interventions for nutrition and mobilization. The investigators will accomplish this by studying the effects of a high protein (HPRO) nutritional treatment as well as NMES intervention have upon muscle wasting and motor strength acutely after SAH. This will be addressed in a prospective trial of SAH patients receiving HRPO with NMES as compared to age and severity-matched SAH patients undergoing standard of care interventions for nutrition and mobilization. Additionally, the study will investigate the impact HPRO and NMES interventions have upon inflammatory cytokines and markers of energy balance. Results of this study will establish evidence for precision nutrition plus early exercise to mitigate the catabolic and inflammatory state produced by SAH to improve muscle, metabolic, and health recovery outcomes.

What's being tested

  • Neuromuscular Electrical Stimulation (NMES)

    Intervention · DEVICE

    Neuromuscular electrical stimulation twice daily during study period.

  • High Protein Supplementation

    Intervention · DIETARY SUPPLEMENT

    High protein supplementation with whey protein shakes taken three times a day during study period.

Study details

Official title
Impact of Neuromuscular Stimulation and High Protein Nutritional Supplementation on Long-term Recovery After Aneurysmal Subarachnoid Hemorrhage.
Sponsor
University of Maryland, Baltimore
Conditions
Subarachnoid Hemorrhage · Muscle Atrophy · Inflammation · Nutritional and Metabolic Disease
Enrolling
30 people
Starts
2017-12-01
Est. completion
2026-10-30
Design
Single-blind, randomized, parallel groups
Record
View on ClinicalTrials.gov ↗